Cover Image
市場調查報告書

Cancer Therapeutics CRC Pty Ltd - 產品平台檢討

Cancer Therapeutics CRC Pty Ltd - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 253707
出版日期 內容資訊 英文 25 Pages
訂單完成後即時交付
價格
Back to Top
Cancer Therapeutics CRC Pty Ltd - 產品平台檢討 Cancer Therapeutics CRC Pty Ltd - Product Pipeline Review - 2015
出版日期: 2015年04月30日 內容資訊: 英文 25 Pages
簡介

Cancer Therapeutics CRC Pty Ltd是總公司在澳洲的製藥企業,進行著癌症治療用低分子藥的藥物研發及開發。關於該公司在低分子癌症治療藥的藥物研發及開發,總括性涵蓋到候補藥的臨床試驗的必要技術、治療藥的對象是乳癌、前列腺癌症、黑色素瘤、肺癌症及腦瘤。

本報告提供Cancer Therapeutics CRC Pty Ltd的治療藥開發平台的現狀及各開發階段比較分析、各藥物標的、作用機制、給藥途徑、分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

目錄

Cancer Therapeutics CRC Pty Ltd的基本資料

  • Cancer Therapeutics CRC Pty Ltd概要
  • 主要資訊
  • 企業資料

Cancer Therapeutics CRC Pty Ltd:R&D概要

  • 主要的治療範圍

Cancer Therapeutics CRC Pty Ltd:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Cancer Therapeutics CRC Pty Ltd:開發中產品概況

  • 初期階段有的開發中產品
    • 藥物研發階段的產品/聯合治療模式

Cancer Therapeutics CRC Pty Ltd:藥物簡介

  • Small Molecule Inhibiting Mitosis for Solid Tumors
  • Small Molecule to Inhibit USP7 for Cancer
  • Small Molecules For Cancer
  • Small Molecules to Inhibit MOZ for Acute Myelocytic Leukemia
  • Small Molecules to Inhibit Ubiquitin E3 Ligase E6AP for Cancer

Cancer Therapeutics CRC Pty Ltd:開發平台分析

  • 各標的
  • 各分子類型
  • 各作用機制

Cancer Therapeutics CRC Pty Ltd:開發暫停中的計劃

Cancer Therapeutics CRC Pty Ltd:總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07008CDB

Summary

Global Markets Direct's, 'Cancer Therapeutics CRC Pty Ltd - Product Pipeline Review - 2015', provides an overview of the Cancer Therapeutics CRC Pty Ltd's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Cancer Therapeutics CRC Pty Ltd's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Cancer Therapeutics CRC Pty Ltd including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Cancer Therapeutics CRC Pty Ltd's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Cancer Therapeutics CRC Pty Ltd's pipeline products

Reasons to buy

  • Evaluate Cancer Therapeutics CRC Pty Ltd's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Cancer Therapeutics CRC Pty Ltd in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Cancer Therapeutics CRC Pty Ltd's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Cancer Therapeutics CRC Pty Ltd and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Cancer Therapeutics CRC Pty Ltd
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Cancer Therapeutics CRC Pty Ltd and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Cancer Therapeutics CRC Pty Ltd Snapshot
    • Cancer Therapeutics CRC Pty Ltd Overview
    • Key Information
    • Key Facts
  • Cancer Therapeutics CRC Pty Ltd - Research and Development Overview
    • Key Therapeutic Areas
  • Cancer Therapeutics CRC Pty Ltd - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Cancer Therapeutics CRC Pty Ltd - Pipeline Products Glance
    • Cancer Therapeutics CRC Pty Ltd - Early Stage Pipeline Products
      • Discovery Products/Combination Treatment Modalities
  • Cancer Therapeutics CRC Pty Ltd - Drug Profiles
    • Small Molecule Inhibiting Mitosis for Solid Tumors
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit USP7 for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules For Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit MOZ for Acute Myelocytic Leukemia
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Ubiquitin E3 Ligase E6AP for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Cancer Therapeutics CRC Pty Ltd - Pipeline Analysis
  • Cancer Therapeutics CRC Pty Ltd - Pipeline Products by Target
  • Cancer Therapeutics CRC Pty Ltd - Pipeline Products by Molecule Type
  • Cancer Therapeutics CRC Pty Ltd - Pipeline Products by Mechanism of Action
  • Cancer Therapeutics CRC Pty Ltd - Dormant Projects
  • Cancer Therapeutics CRC Pty Ltd - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Cancer Therapeutics CRC Pty Ltd, Key Information
  • Cancer Therapeutics CRC Pty Ltd, Key Facts
  • Cancer Therapeutics CRC Pty Ltd - Pipeline by Indication, 2015
  • Cancer Therapeutics CRC Pty Ltd - Pipeline by Stage of Development, 2015
  • Cancer Therapeutics CRC Pty Ltd - Monotherapy Products in Pipeline, 2015
  • Cancer Therapeutics CRC Pty Ltd - Partnered Products in Pipeline, 2015
  • Cancer Therapeutics CRC Pty Ltd - Partnered Products/ Combination Treatment Modalities, 2015
  • Cancer Therapeutics CRC Pty Ltd - Out-Licensed Products in Pipeline, 2015
  • Cancer Therapeutics CRC Pty Ltd - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Cancer Therapeutics CRC Pty Ltd - Discovery, 2015
  • Cancer Therapeutics CRC Pty Ltd - Pipeline by Target, 2015
  • Cancer Therapeutics CRC Pty Ltd - Pipeline by Molecule Type, 2015
  • Cancer Therapeutics CRC Pty Ltd - Pipeline Products by Mechanism of Action, 2015
  • Cancer Therapeutics CRC Pty Ltd - Dormant Developmental Projects,2015

List of Figures

  • Cancer Therapeutics CRC Pty Ltd - Pipeline by Top 10 Indication, 2015
  • Cancer Therapeutics CRC Pty Ltd - Partnered Products in Pipeline, 2015
  • Cancer Therapeutics CRC Pty Ltd - Pipeline by Top 10 Molecule Type, 2015
  • Cancer Therapeutics CRC Pty Ltd - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top